Danish pharma Novo Nordisk is expanding its R&D capabilities in Boston, Massachusetts, US, which will lead to the closure of a facility in Indianapolis and a...

Danish pharma Novo Nordisk has announced plans to invest 5.4 billion Danish kroner to expand its existing facilities in Bagsværd.

The CEOs of seven multinational pharmaceutical companies have announced that they are taking joint action to achieve near-term emissions reduction targets and accelerate...

Denmark’s Novo Nordisk has entered into a global license and development with compatriot biotech Zealand Pharma for the latter’s Zegalogue (dasiglucagon) injectable...

Danish pharma Novo Nordisk has agreed to acquire US clinical-stage biopharma Forma Therapeutics in a deal worth $1.1 billion that will expand its blood disorders...

Danish companies Novozymes and Novo Nordisk Pharmatech are teaming up to develop technical enzymes to support biopharma processing. The companies aim to develop high...

Danish pharma Novo Nordisk has agreed to buy Dicerna Pharmaceuticals, offering $3.3 billion for the US biopharma and its ribonucleic acid interference (RNAi) platform.

Danish drugmaker Novo Nordisk has acquired Prothena’s clinical-stage stage antibody PRX004 and broader ATTR amyloidosis program, gaining full global rights to the...